In familial ALS, where SOD1 mutations heighten oxidative impairment, CRISPR-directed gene correction has triumphed in a preclinical model with reductions in motor neuron death and extended lifespans for the ALS-affected. Here, SOD1 is linked to amyotrophic lateral sclerosis.